Market News Call

Stocks Highlights: Gilead Sciences Inc. (NASDAQ:GILD), Voxeljet AG (ADR) (NYSE:VJET), SolarCity Corporation (NASDAQ:SCTY)

Lakeway, NY — (MARKET NEWS CALL) — 7/18/2014—, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on SolarCity Corporation (NASDAQ:SCTY), Voxeljet AG (ADR) (NYSE:VJET), Gilead Sciences Inc. (NASDAQ:GILD).

SolarCity Corporation (NASDAQ:SCTY)’s shares dropped 1.80% to $63.69. SCTY’s stock had its price target increased by JPMorgan Chase & Co. from $72.00 to $77.00 in a research report sent to investors on July 16. The firm currently has an overweight rating on the stock.

Should Investors Buy SCTY After The Recent Development? Find Out Here

The company last issued its quarterly earnings data on May 7. SCTY reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimate of ($0.74) by $0.48. The company had revenue of $63.54 million for the quarter, compared to the consensus estimate of $53.39 million.

Voxeljet AG (ADR) (NYSE:VJET)’s shares declined 1.77% to $18.30. Stock analysts at Brean Capital began coverage on shares of Voxeljet AG in a report issued on June 20. The firm set a “hold” rating on the stock.

Is VJET Going To Rise or Fall After Today’s Price Action? Find Out Here

Additionally, the company on June 9 announced that it has appointed David Tait as general manager of its U.S. industrial 3D printing service center, located in Canton, MI. In his role as voxeljet’s U.S. general manager, Tait will have overall responsibility for building out voxeljet’s U.S. team, as well as sales and marketing of the company’s 3D printers and services business in the U.S. and Canada.

Gilead Sciences Inc. (NASDAQ:GILD)’s shares declined 2.22% to $85.07. The company announced that its second quarter 2014 financial results will be released on July 23, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2014 and provide a general business update. The conference call will be accessible via the internet from the company’s website.

Can Traders Buy GILD After The Solid Rally? Get Free Trend Analysis Here

Additionally, Two U.S. senators asked Gilead Sciences Inc. to produce documents explaining why its new hepatitis C drug is priced at $84,000, raising renewed concerns over the high costs to taxpayers. In a letter sent on July 11, Sen. Ron Wyden, D-Oregon, and Sen.

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.


Tags: , ,

Comments are closed.